Lycium barbarum polysaccharide ameliorates Sjögren's syndrome. - GreenMedInfo Summary
Lycium barbarum Polysaccharide Ameliorates Sjögren's Syndrome in a Murine Model.
Mol Nutr Food Res. 2021 06 ;65(11):e2001118. Epub 2021 May 5. PMID: 33825332
SCOPE: This study aims to evaluate the therapeutic efficacy and mechanisms of Lycium barbarum polysaccharide (LBP) in primary Sjögren's syndrome (pSS).
METHODS AND RESULTS: Non-obese diabetic mice (the pSS model) are randomly divided into four groups: Low dose LBP (LBP.L, 5 mg kg d), high dose LBP (10 mg kg d), low dose interleukin (IL)-2 (25 000 IU/d), and control (saline water). Drugs were treated for 12 weeks. LBP.L significantly reduces the salivary gland inflammation compared with the control group (histological score pvs = 0.019; foci number: pvs = 0.038). LBP.L also remarkably reduces the effector follicular helper T (Tfh) cells and the CD4IL-17Ahelper T (Th17) cells in both spleen and cervical lymph node (cLN) cells. Additionally, the ratios of regulatory T cell (Treg)/Tfh cells and Treg/Th17 cells are substantially increased in mice treated with LBP.L in both spleen and cLNs. LBP also inhibits Th17 and Tfh cells and markedly increases the Treg/Tfh ratio in human peripheral blood mononuclear cells.
CONCLUSION: LBP.L inhibits the progression of pSS in mice, associated with modulation of T cell differentiation.